Page 13 - Serum Institute Of India

India emerges global manufacturing hub for Covid-19 vaccine Sputnik V

Gland Pharma to make 252 mn doses, Hetero 100 mn doses, Strides may also join the fray

Govt places new purchase order with SII for 100 mn doses of Covishield

The price was fixed at Rs 157.50 a dose, including GST

Vaccinating India: What next?

We must pull out all the stops to win the race against the virus. And trust each other to do the right thing

Concerns over Oxford Covid-19 vaccine likely to impact export demand

Vaccine exports picked up last month; Serum shipped 11.9 mn to WHO-Gavi pool

Novavax's coronavirus vaccine 96% effective in UK late-stage trial

Company plans to produce its jab at eight sites, including Serum Institute

Adar Poonawalla-backed Svasti Microfinance to raise Rs 150 crore

This is likely to conclude by the third quarter of FY22, said Arunkumar Padmanabhan, co-founder of Svasti Micro­finance

Nepal receives 348,000 doses of made-in-India Covid-19 vaccines

The first COVAX shipment of 348,000 doses of AstraZeneca 'Covishield' vaccines arrived in Kathmandu, the embassy said in a tweet

SII seeks govt intervention over US ban on export of vaccine raw materials

US government has invoked the Defence Production Act because of which the firm is facing difficulties in importing necessary products, says director, government and regulatory affairs at Pune-based SI

India's massive Covid vaccine campaign boosted by PM Modi receiving shot

Almost 21 million shots have been administered in India so far, up from 5.4 million a month ago

Raw material shortage may affect scaling up of Covishield production

Last week, Adar Poonawalla had said on a World Bank panel that a US law blocking the export of key items like bags and filters will likely cause "serious bottlenecks" in vaccine production

10 mn doses from India won't impact poor nations' vaccine access, says UK

UK Vaccine Deployment Minister Nadhim Zahawi has defended a shipment of 10 million doses of Covishield en route from India amid some concerns that it would impact supplies of poorer nations

WHO head wants Covid-19 vaccine patents waived to increase supply

The head of the World Health Organization called for patent rights to be waived until the end of the pandemic so that vaccine supplies can be dramatically increased

US export curbs can limit Covid shot production, availability: Poonawalla

The production of coronavirus vaccines and scaling up global availability could be seriously limited due to ban on exports of critical raw materials by the US, according to SII CEO Adar Poonawalla

US ban on export of critical raw materials to limit vaccine supply: Serum

SII, the world's biggest vaccine maker, has licensed the AstraZeneca/Oxford University product and will soon start bulk-manufacturing the Novavax shot

India Coronavirus Dispatch: New computational tool to track Covid mutations

Parents more ready to send kids to school, trial candidates wonder if they got vaccine or placebo, Antibodies appear faster if exposed to virus earlier-news relevant to India's fight against Covid-19

Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection

Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot

Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results

Covaxin demonstrates significant immunogenicity against the rapidly emerging variants, says Bharat Biotech CMD

UK to receive 10 mn AstraZeneca vaccine doses from India's Serum Institute

SII, the world's largest vaccine manufacturer by volume, is mass producing the AstraZeneca vaccine, developed with Oxford University, for dozens of poor and middle-income countries

COVAX vaccine programme to deliver 237 mn doses to 142 nations by end-May

The timeline for the delivery of doses, made by AstraZeneca and by India's Serum Institute, will be split into separate two-month schedules, COVAX said in a statement

European Union drug regulator audits manufacturing site of Serum Institute

AstraZeneca Chief Executive (CEO) Pascal Soriot has indicated that the company may look at factories outside of the EU to meet the supply commitments.